Nivolumab-relatlimab Combo for Colorectal Cancer
(RELATIVITY-123 Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial is testing a combination of two drugs, relatlimab and nivolumab, for patients with a certain type of colorectal cancer who haven't responded to other treatments. The drugs help the immune system attack the cancer.
Will I have to stop taking my current medications?
The trial information does not specify if you need to stop taking your current medications. However, it does exclude those who have had prior treatment with certain immunotherapies, regorafenib, or TAS-102.
Is the Nivolumab-relatlimab combo generally safe for humans?
What makes the Nivolumab-relatlimab combo unique for colorectal cancer treatment?
The Nivolumab-relatlimab combo is unique because it combines immunotherapy (using the body's immune system to fight cancer) with targeted therapies like regorafenib and TAS-102, which are used for patients whose cancer has not responded to standard chemotherapy. This combination aims to enhance the effectiveness of treatment by using different mechanisms to attack the cancer.23467
What data supports the effectiveness of the drug Nivolumab-relatlimab FDC, Regorafenib, Stivarga, Regorafenib, BAY 73-4506, Regonix, TAS-102, Trifluridine/tipiracil hydrochloride mixture, TAS-102, Lonsurf for colorectal cancer?
Who Is on the Research Team?
Bristol-Myers Squibb
Principal Investigator
Bristol-Myers Squibb
Are You a Good Fit for This Trial?
This trial is for adults with metastatic colorectal cancer that's not microsatellite instability high (MSI-H)/deficient mismatch repair (dMMR). They must have tried 1-4 standard treatments including specific chemotherapy and targeted drugs, depending on their genetic makeup. People can't join if they've had certain heart issues, untreated brain metastases, prior immunotherapy or the study drugs Regorafenib/TAS-102.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive either the nivolumab-relatlimab fixed-dose combination or treatment with Regorafenib or TAS-102
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Nivolumab-relatlimab FDC
- Regorafenib
- TAS-102
Find a Clinic Near You
Who Is Running the Clinical Trial?
Bristol-Myers Squibb
Lead Sponsor
Christopher Boerner
Bristol-Myers Squibb
Chief Executive Officer since 2023
PhD in Business Administration from the Haas School of Business, University of California, Berkeley; BA in Economics and History from Washington University in St. Louis
Deepak L. Bhatt
Bristol-Myers Squibb
Chief Medical Officer since 2024
MD from Yale University; MSc in Clinical Epidemiology from the University of Pennsylvania